Search results
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
The Pendulum· 3 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced ...
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 2 days agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
Phio Pharmaceuticals advances to next dose in cancer trial By Investing.com
Investing.com· 7 days agoPhio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company specializing in gene silencing...
Filinvest allocates P1.1B for San Mateo residential project - BusinessWorld Online
BusinessWorld· 22 hours agoPRESTIGE by Filinvest said it has allocated P1.1 billion in Celestia, a residential project in Timberland Heights in San Mateo, Rizal. “Under the top-end portfolio of Prestige by Filinvest, ...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI...
Benzinga· 5 days agoREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
Merck to Acquire EyeBio
New Jersey Business Magazine· 6 days agoEyeBio is developing a pipeline of clinical and preclinical candidates for the prevention and treatment of vision loss associated with retinal vascular...
Merck to Acquire EyeBio
Morningstar· 6 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the ...
Are Investors Undervaluing Nagarro SE (FRA:NA9) By 41%?
Simply Wall St. via Yahoo Finance· 1 day agoWe discount the terminal cash flows to today's value at a cost of equity of 6.2%. Terminal Value...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 4 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase ...
UnitedCFX.com - Trusted Partner in Automated AI Trading
Digital Journal· 1 day ago...Corp in Revolutionary Room Temperature SPAD Technology TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC...
